Posted by Michael Wonder on 27 Aug 2017
European Commission grants approval for Mavenclad (cladribine tablets)
25 August 2017 - First oral short-course treatment for highly active relapsing multiple sclerosis now approved in Europe.
Merck today announced that the European Commission has granted marketing authorization for Mavenclad 10 mg (cladribine tablets) for the treatment of highly active relapsing multiple sclerosis in the 28 countries of the European Union in addition to Norway, Liechtenstein and Iceland.
Mavenclad is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active relapsing multiple sclerosis, including disability progression, annualised relapse rate and magnetic resonance imaging activity.
